Is it Time to Transform Our Treatment Of Type 2 Diabetes

Is it Time to Transform Our Treatment Of Type 2 Diabetes

This meeting comprised two sessions: the morning session centred around glucagon-like peptide-1 receptor (GLP-1R) agonists and SGLT-2 inhibitors, a new class of glucose-lowering compounds, while the afternoon session focused on new results of cardiovascular safety studies with diabetes medications,...

Full description

Bibliographic Details
Main Authors: Michael Nauck, Dídac Mauricio, Anthony Barnett, Tina Vilsbøll, Samy Hadjadj, Peter Rossing, Edoardo Mannucci, Harald Darius, Chantal Mathieu
Format: Article
Language:English
Published: European Medical Journal 2013-10-01
Series:European Medical Journal Diabetes
Subjects:
EASD
European Association for the Study of Diabetes
Type 2 Diabetes
Online Access:http://emjreviews.com/wp-content/uploads/Is-it-Time-to-Transform-Our-Treatment-Of-Type-2-Diabetes_-copy.pdf
id doaj-d6559e1829db4644b219a1922fcb4dee
record_format Article
spelling doaj-d6559e1829db4644b219a1922fcb4dee2020-11-25T00:18:57ZengEuropean Medical JournalEuropean Medical Journal Diabetes2054-61812013-10-01112229Is it Time to Transform Our Treatment Of Type 2 DiabetesMichael Nauck0Dídac Mauricio1Anthony Barnett2Tina Vilsbøll3Samy Hadjadj4Peter Rossing5Edoardo Mannucci6Harald Darius7Chantal Mathieu8Head, Diabeteszentrium Bad Lauterberg, Harz, GermanyChief Physician, Department of Endocrinology & Nutrition, Germans Trias i Pujol University Hospital, Badalona, SpainProfessor of Medicine, University of Birmingham, UKProfessor of Medicine, Head of the Diabetes Research Division, Gentofte Hospital, Copenhagen, DenmarkDepartment of Diabetology, Poitiers University Hospital, FranceHead of Research, Steno Diabetes Centre, Professor of Diabetic Angiopathy, Aarus University, University of Copenhagen, DenmarkDirector, Diabetes Agency of Careggi Teaching Hospital, Florence, ItalyDirector, Department of Cardiology, Vascular Medicine and Intensive Care Medicines, Vivantes Neukölln Medical Centre, Berlin, GermanyProfessor of Medicine, Katholieke University, Leuven, BelgiumThis meeting comprised two sessions: the morning session centred around glucagon-like peptide-1 receptor (GLP-1R) agonists and SGLT-2 inhibitors, a new class of glucose-lowering compounds, while the afternoon session focused on new results of cardiovascular safety studies with diabetes medications, with special attention to the SAVOR-TIMI trial of saxagliptin.http://emjreviews.com/wp-content/uploads/Is-it-Time-to-Transform-Our-Treatment-Of-Type-2-Diabetes_-copy.pdfEASDEuropean Association for the Study of DiabetesType 2 Diabetes
collection DOAJ
language English
format Article
sources DOAJ
author Michael Nauck
Dídac Mauricio
Anthony Barnett
Tina Vilsbøll
Samy Hadjadj
Peter Rossing
Edoardo Mannucci
Harald Darius
Chantal Mathieu
spellingShingle Michael Nauck
Dídac Mauricio
Anthony Barnett
Tina Vilsbøll
Samy Hadjadj
Peter Rossing
Edoardo Mannucci
Harald Darius
Chantal Mathieu
Is it Time to Transform Our Treatment Of Type 2 Diabetes
European Medical Journal Diabetes
EASD
European Association for the Study of Diabetes
Type 2 Diabetes
author_facet Michael Nauck
Dídac Mauricio
Anthony Barnett
Tina Vilsbøll
Samy Hadjadj
Peter Rossing
Edoardo Mannucci
Harald Darius
Chantal Mathieu
author_sort Michael Nauck
title Is it Time to Transform Our Treatment Of Type 2 Diabetes
title_short Is it Time to Transform Our Treatment Of Type 2 Diabetes
title_full Is it Time to Transform Our Treatment Of Type 2 Diabetes
title_fullStr Is it Time to Transform Our Treatment Of Type 2 Diabetes
title_full_unstemmed Is it Time to Transform Our Treatment Of Type 2 Diabetes
title_sort is it time to transform our treatment of type 2 diabetes
publisher European Medical Journal
series European Medical Journal Diabetes
issn 2054-6181
publishDate 2013-10-01
description This meeting comprised two sessions: the morning session centred around glucagon-like peptide-1 receptor (GLP-1R) agonists and SGLT-2 inhibitors, a new class of glucose-lowering compounds, while the afternoon session focused on new results of cardiovascular safety studies with diabetes medications, with special attention to the SAVOR-TIMI trial of saxagliptin.
topic EASD
European Association for the Study of Diabetes
Type 2 Diabetes
url http://emjreviews.com/wp-content/uploads/Is-it-Time-to-Transform-Our-Treatment-Of-Type-2-Diabetes_-copy.pdf
work_keys_str_mv AT michaelnauck isittimetotransformourtreatmentoftype2diabetes
AT didacmauricio isittimetotransformourtreatmentoftype2diabetes
AT anthonybarnett isittimetotransformourtreatmentoftype2diabetes
AT tinavilsbøll isittimetotransformourtreatmentoftype2diabetes
AT samyhadjadj isittimetotransformourtreatmentoftype2diabetes
AT peterrossing isittimetotransformourtreatmentoftype2diabetes
AT edoardomannucci isittimetotransformourtreatmentoftype2diabetes
AT haralddarius isittimetotransformourtreatmentoftype2diabetes
AT chantalmathieu isittimetotransformourtreatmentoftype2diabetes
_version_ 1725374239538675712

Similar Items